Abstract
Background: Autoimmune disease is a refractory disease. Accumulating Evidence has revealed that the manipulation of mesenchymal stem cells may have the potential to control or even treat autoimmune diseases. Human gingiva-derived mesenchymal stem cells (GMSCs) are emerging as a new line of mesenchymal stem cells that have displayed some potential advantages in controlling and treating autoimmune diseases.
Objective: In this review, we briefly update the current understanding on the biology of GMSCs and their effects on preventing and treating autoimmune diseases.
Conclusion: The availability of gingival mesenchymal stem cells (GMSCs), together with their potent capacity of multi-directional differentiation and inflammatory modulation, making GMSCs an ideal subtype of MSCs in treating autoimmune disease. Our and other studies have launched the earliest appraisal on GMSCs and carried out a lot of biological researches. The clinical trial of GMSCs on patients with autoimmune diseases will further approve their therapeutic effects, as well as its cellular and molecular mechanisms.
Keywords: Autoimmune diseases, mesenchymal stem cells, human gingiva-derived mesenchymal stem cells, bone marrowderived mesenchymal stem cells, cell therapy.
Current Stem Cell Research & Therapy
Title:Updates on GMSCs Treatment for Autoimmune Diseases
Volume: 13 Issue: 5
Author(s): Feng Huang, Zhong Ming Liu and Song Guo Zheng*
Affiliation:
- Department of Medicine, Milton S. Hershey Medical Center, Penn State University, Hershey, PA, 17033,United States
Keywords: Autoimmune diseases, mesenchymal stem cells, human gingiva-derived mesenchymal stem cells, bone marrowderived mesenchymal stem cells, cell therapy.
Abstract: Background: Autoimmune disease is a refractory disease. Accumulating Evidence has revealed that the manipulation of mesenchymal stem cells may have the potential to control or even treat autoimmune diseases. Human gingiva-derived mesenchymal stem cells (GMSCs) are emerging as a new line of mesenchymal stem cells that have displayed some potential advantages in controlling and treating autoimmune diseases.
Objective: In this review, we briefly update the current understanding on the biology of GMSCs and their effects on preventing and treating autoimmune diseases.
Conclusion: The availability of gingival mesenchymal stem cells (GMSCs), together with their potent capacity of multi-directional differentiation and inflammatory modulation, making GMSCs an ideal subtype of MSCs in treating autoimmune disease. Our and other studies have launched the earliest appraisal on GMSCs and carried out a lot of biological researches. The clinical trial of GMSCs on patients with autoimmune diseases will further approve their therapeutic effects, as well as its cellular and molecular mechanisms.
Export Options
About this article
Cite this article as:
Huang Feng , Liu Ming Zhong and Zheng Guo Song *, Updates on GMSCs Treatment for Autoimmune Diseases, Current Stem Cell Research & Therapy 2018; 13 (5) . https://dx.doi.org/10.2174/1574888X13666180220141114
DOI https://dx.doi.org/10.2174/1574888X13666180220141114 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SAGE Application in Hematological Research
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Innate Immunity and Autoimmune Disease (Guest Editors: F. Susan Wong and Li Wen)]
Current Molecular Medicine Phospholipid/Bile Salt Based Novel Mixed Nanomicelles of Methotrexate Co-encapsulated with Sesamol: Preparation, Characterization, and Evaluation of Antiradical Effects In Vitro
Current Nanomedicine Tissue-specific Glucocorticoid Signaling May Determine the Resistance Against Glucocorticoids in Autoimmune Diseases
Current Medicinal Chemistry Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Pattern Recognition Receptors and Control of Innate Immunity: Role of Nucleic Acids
Current Pharmaceutical Biotechnology Stem Cell-Based Therapies and Immunomodulatory Approaches in Newly Diagnosed Type 1 Diabetes
Current Stem Cell Research & Therapy Synthetic Peptides in the Diagnosis of Neurological Diseases
Current Protein & Peptide Science Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design The Impact of Fc Receptors on the Development of Autoimmune Diseases
Current Pharmaceutical Design Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design Assessment of Endothelial Function by Positron Emission Tomography
Current Cardiology Reviews New Insights into the Roles of Endolysosomal Cathepsins in the Pathogenesis of Alzheimers Disease: Cathepsin Inhibitors as Potential Therapeutics
CNS & Neurological Disorders - Drug Targets Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Benefits of Regulating Inflammation in Autoimmunity
Inflammation & Allergy - Drug Targets (Discontinued) Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Interleukin-7: a key Mediator in T Cell-driven Autoimmunity, Inflammation, and Tissue Destruction
Current Pharmaceutical Design Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Genomic Strategies in Pharmacology of Asthma and Autoimmunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry